TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05733832

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transitional Liver Clinic (TLC)
Description: Participants in this intervention receive additional attention from their Hepatology providers in terms of an additional call/telemedicine visit and more specific/additional attention from their Hepatology APP (advanced practice provider) based on individual patient needs
Study: NCT05885438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT workshop
Description: This workshop is a brief behavioral intervention that teaches acceptance and commitment therapy skills (e.g., values clarification, acceptance, committed action) to approach healthy living.
Study: NCT05007054

Intervention type: PROCEDURE
Intervention: PCI or CABG
Description: The PCI performed following current standard guidelines. All patients were pre-treated with aspirin and clopidogrel before catheterization. Thereafter, heparin (70-100 IU/kg) was administered before PCI, however, the use of glycoprotein IIb/IIIa inhibitors was at the physician's discretion. Dual-antiplatelet medication was administered to the patients after PCI for at least 12 months. For CABG, the left internal mammary artery was routinely used to graft to the left anterior descending artery and completed by venous grafts to other coronary branches with standard bypass techniques. The procedure was performed by surgeons experienced in on-pump or of-pump surgery at the operator's discretion.

Intervention type: PROCEDURE
Intervention: PCI or CABG
Description: The PCI performed following current standard guidelines. All patients were pre-treated with aspirin and clopidogrel before catheterization. Thereafter, heparin (70-100 IU/kg) was administered before PCI, however, the use of glycoprotein IIb/IIIa inhibitors was at the physician's discretion. Dual-antiplatelet medication was administered to the patients after PCI for at least 12 months. For CABG, the left internal mammary artery was routinely used to graft to the left anterior descending artery and completed by venous grafts to other coronary branches with standard bypass techniques. The procedure was performed by surgeons experienced in on-pump or of-pump surgery at the operator's discretion.
Study: NCT05375032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling combined with cognitive tasks
Description: A 30-minute session of Forced Cycling aerobic exercise performed with lower limbs and free active cycling performed with upper limbs combined with cognitive stimuli. An intelligent cycle ergometer (Motomed Viva 2 Parkinson) will be used, at a reserve heart rate of 55-70% (Borg scale 12-14) during the active part. The forced cycling program will consist of a 6-minute passive warm-up part (40-60 RPM), a 20-minute active part (90 RPM), and a 4-minute passive cool down (40 RPM). The cognitive task will be a PowerPoint presentation structured in a way that is consistent with the phases of the cycling program. The passive phases (6 minutes of warm-up and 4 minutes of passive cycling back to cool down), images of the nearby environment will be played. For the active phase (20 minutes of assisted active cycling) the PowerPoint presentation will be structured with tasks related to: orientation, memory, calculation, language, similarities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cycling
Description: A 30-minute session of Forced Cycling aerobic exercise performed with lower limbs and free active cycling performed with upper limbs combined with cognitive stimuli. An intelligent cycle ergometer (Motomed Viva 2 Parkinson) will be used, at a reserve heart rate of 55-70% (Borg scale 12-14) during the active part. The forced cycling program will consist of a 6-minute passive warm-up part (40-60 RPM), a 20-minute active part (90 RPM), and a 4-minute passive cool down (40 RPM).
Study: NCT05962528

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Soft lens
Description: Patients were randomly fitted with five different designs of soft lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft lens
Description: Patients were randomly fitted with five different designs of soft lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft lens
Description: Patients were randomly fitted with five different designs of soft lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft lens
Description: Patients were randomly fitted with five different designs of soft lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft lens
Description: Patients were randomly fitted with five different designs of soft lenses
Study: NCT05252650

Intervention type: BEHAVIORAL
Intervention: pain
Description: postoperative pain

Intervention type: BEHAVIORAL
Intervention: pain
Description: postoperative pain
Study: NCT06063811

Intervention type: OTHER
Intervention: Ablation
Description: VT ablation
Study: NCT05130853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills and Neurocognitive Individualized Training (SoCIAL)
Description: SoCIAL is composed of two modules:~1. Social Cognition Training The Emotions recognition training will train the subject's ability in discriminating between different emotional states through photos and videos. The Theory of Mind (ToM) training will help subjects discriminate between emotional expressions in social contexts and understand other people's mental state with videos that display actors expressing several emotional states. More details in Palumbo et al., 2017.~2. Narrative Enhancement Training The narrative enhancement training consists in story-telling exercises focused on improving the subject's capacity to comprehend his/her emotional experience.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatmment-as-usual
Description: Subjects that will be randomized in this group will receive their treatment as usual for the whole length of the study. TAU includes all the psychiatric therapies (pharmacological, psychological, occupational etc) that subjects may have begun before study's enrollment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatmment-as-usual
Description: Subjects that will be randomized in this group will receive their treatment as usual for the whole length of the study. TAU includes all the psychiatric therapies (pharmacological, psychological, occupational etc) that subjects may have begun before study's enrollment.
Study: NCT06147284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventive interventions
Description: Parallel randomized controlled trial

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventive interventions
Description: Parallel randomized controlled trial

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventive interventions
Description: Parallel randomized controlled trial

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventive interventions
Description: Parallel randomized controlled trial
Study: NCT06254768

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor
Description: its a device used to measure glucose from interstitial fluids and provides feedback regarding the same every 5 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor
Description: its a device used to measure glucose from interstitial fluids and provides feedback regarding the same every 5 minutes.
Study: NCT05050994

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: Children with symptomatic secondary splenomegaly will receive partial microwave ablation of spleen (up to 40-50% of total volume)
Study: NCT05179226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Derisomaltose
Description: All subjects will be treated with Ferric derisomaltose 20 mg/kg at baseline visit except for 12 subjects included in the PK-group, who will be treated with 10 mg/kg
Study: NCT06140589

Intervention type: DRUG
Intervention: Cadonilimab
Description: The intravenous dose of Cadonilimab was 10mg/kg, and every 3 weeks was a course of treatment; Or 6mg/kg, every 2 weeks for a course of treatment

Intervention type: DRUG
Intervention: Cadonilimab
Description: The intravenous dose of Cadonilimab was 10mg/kg, and every 3 weeks was a course of treatment; Or 6mg/kg, every 2 weeks for a course of treatment
Study: NCT05674656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Rilpivirine FDC
Description: Dolutegravir/Rilpivirine will be administered.
Study: NCT05376150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN1101 10 mg
Description: XEN1101 oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN1101 20 mg
Description: XEN1101 oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT05459181

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HeartCare
Description: Using HeartCare platform as a tool to successfully augment immunosuppressant agents through regular surveillance allowing minimization of doses and number of agents.
Study: NCT05766592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LGBTQ-affirmative CBT
Description: 16-session LGBTQ-affirmative psychotherapy using cognitive behavioral techniques

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABFT-SGM
Description: 16-session attachment-based family therapy for sexual and gender minority young adults and their nonaccepting parents
Study: NCT04029883

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Message
Description: A key insight from BE is that people typically are initially highly motivated to change their behavior, but their enthusiasm declines over time.103 To keep the importance of routinizing pill-taking salient (i.e. high on a person's mental priority list), we will send daily text messages using a freely available web platform.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Economic Incentive
Description: In this group, participants will be eligible for a prize drawing if they take their medication within +/- 1 hour of the time they carry out their existing routine behavior on at least 80% of days between clinic visits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message
Description: A key insight from BE is that people typically are initially highly motivated to change their behavior, but their enthusiasm declines over time.103 To keep the importance of routinizing pill-taking salient (i.e. high on a person's mental priority list), we will send daily text messages using a freely available web platform.
Study: NCT05506657

Intervention type: OTHER
Group type: OTHER
Intervention: State Counselor-Coordinated Services
Description: A counselor affiliated with the New Jersey State Division of Vocational Rehabilitation Services coordinates services that consider the participant's condition, needs and goals. Services participants may receive include:~* Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~* Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~* Help completing applications for services.~* Assistance communicating with my employer about my needs and ways to accommodate them.~* Referrals to and services from other health care or technology providers.
Study: NCT06064279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Tol like receptor 3 agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG
Description: pooled IVIG
Study: NCT06378008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSPS toothpaste
Description: Toothpaste containing 5.0% weight/weight (w/w) CSPS.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular fluoride toothpaste (Crest Cavity Protection)
Description: Regular fluoride toothpaste containing 1100 parts per million (ppm) fluoride.
Study: NCT06553937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan and Tadalafil
Description: 1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macitentan and Tadalafil
Description: 1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PrOpsynvi® Film-Coated Tablets
Description: 1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrOpsynvi® Film-Coated Tablets
Description: 1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
Study: NCT04837716

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV
Study: NCT05411029

Intervention type: DIAGNOSTIC_TEST
Intervention: 24 hour blood pressure (BP) monitoring
Description: 24-hour ambulatory BP measuring device and blood pressures will be measured every 20 minutes to half hour

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: Measurements will include electroencephalogram, electromyogram, electrooculogram, electrocardiogram, breathing patterns of chest and abdomen, nasal and oral airflow and oxygen saturation. Sleep stages and apneas will be scored in accordance with validated American Academy of Sleep Medicine standards.
Study: NCT04935710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPE2Thrive
Description: Cognitive Behavioral Therapy-based program to help teens deal with anxiety, stress and depression by showing them how to develop skills needed to stop negative thoughts and start thinking and behaving in more positive ways.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Children at risk who are not randomized to COPE2Thrive at any point of time serve as the control group.
Study: NCT05893888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRV211 (Intraoperative Cisplatin System)
Description: PRV211 system is comprised of two parts, a liquid permeation enhancer (PE) and cisplatin patch. The permeation is brushed onto the resected tumor bed and after 5 minutes the patch can be applied directly over the same area. Apply up to 2 layers of the PRV211 system to the tumor bed post-resection. The duration of the PRV211 treatment takes approximately 10-20 minutes and then the surgeon can continue as planned with the rest of the standard of care procedure. The proposed starting dose is 0.5 mg/cm2 of cisplatin on the tumor bed. This approach can be safe and effective in preventing locoregional recurrence after surgery and eliminating high-risk factors for local recurrence, such as dysplasia at the margins.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRV111 (Cisplatin Transmucosal System)
Description: PRV111 (Cisplatin Transmucosal System) is a thin, 2-layer, matrix-type, transmucosal patch consisting of a chitosan matrix layer embedded with cisplatin loaded chitosan particles (CLPs) and a non-woven fabric adhesive unidirectional backing, which is applied to the matrix layer during manufacturing. The patch is self-adhesive. In addition to the PRV111 patch, a separately packaged Permeation Enhancer (PE) Powder for Reconstitution used in conjunction with PRV111. The reconstituted PE Solution is intended to improve the absorption of the cisplatin active ingredient and will be applied prior to patch application.
Study: NCT05494190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60 mg/m2 i.v. day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60 mg/m2 i.v. day 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 750 mg/m2 po bid day 1-14

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy
Description: Radiotherapy: using intensity-modulated radiation therapy (IMRT)~Gross tumor volume (GTV) for primary tumor: 66-70 Gy in total, 2.0\~2.2 Gy per day, 5 days per week~Clinical target volume (CTV) for lesions closely related to the primary lesion and metastatic lymph nodes: 65\~70 Gy in total, 1.7\~2.0 Gy per day, 5 days per week~Prophylactic irradiation for sites of suspected subclinical spread: 50\~60 Gy in total, 1.7\~2.0 Gy per day, 5 days per week~Concurrent chemotherapy: cisplatin 80 mg/m2 on days 1-3 every 3 weeks.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant chemoradiotherapy
Description: Radiotherapy: using intensity-modulated radiation therapy (IMRT)~Gross tumor volume (GTV) for primary tumor: 66-70 Gy in total, 2.0\~2.2 Gy per day, 5 days per week~Clinical target volume (CTV) for lesions closely related to the primary lesion and metastatic lymph nodes: 65\~70 Gy in total, 1.7\~2.0 Gy per day, 5 days per week~Prophylactic irradiation for sites of suspected subclinical spread: 50\~60 Gy in total, 1.7\~2.0 Gy per day, 5 days per week~Concurrent chemotherapy: cisplatin 80 mg/m2 on days 1-3 every 3 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Neck dissection and primary tumor resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Neck dissection and primary tumor resection
Study: NCT05826314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boxing training
Description: Training protocol will be held for 24 weeks, twice per week/ 45 min per sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Training protocol will be held for 24 weeks, twice per week/ 45 min per sessions.
Study: NCT05271240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation
Description: Subjects who are assigned to the IA BV+TMZ/RT group (Treatment Group), in addition to your standard of care cancer treatment, you will have a dose of bevacizumab delivered directly to your brain through superselective intra-cranial intra-arterial catheterization of the arteries that supply blood to your brain tumor along with the start of the initial 42 day oral temozolomide treatment. IA BV will be repeated every three months for a total of 3 infusions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide and Radiation Alone
Description: Subjects who are assigned to the TMZ/RT alone group (Control Group) you will receive standard of care cancer treatment that involves a daily oral dose of temozolomide for 42 days with radiation to the tumor followed by 28 days of rest and then repeated maintenance treatment cycles of daily oral temozolomide 5 days on and 23 days off.
Study: NCT05913232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H-1337 0.6%
Description: ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H-1337 1.0%
Description: ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H-1337 1.0%
Description: ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H-1337 Placebo
Description: ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol 0.5%
Description: ophthalmic solution
Study: NCT05227196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide D Dose 1
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide D Dose 1
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide D Dose 1
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide D Dose 1
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide D Dose 1
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide D Dose 2
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide D Dose 2
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide D Dose 2
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide D Dose 3
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide D Dose 3
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Dose 4
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Dose 4
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Dose 4
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Dose 4
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Dose 4
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Dose 5
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Dose 5
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Dose 5
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Dose 6
Description: Tablet given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Dose 6
Description: Tablet given orally
Study: NCT04907357

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Each rTMS session will consist of 75 rTMS trains of 10 Hz for 4 seconds (40 pulses per train) with inter-train interval (ITI) of 11 seconds (a total of 3000 stimuli per session) over the left dorsolateral prefrontal cortex (DLPFC).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham (Placebo)
Description: Each sham rTMS session will consist of 75 rTMS trains of 10 Hz for 4 seconds (40 pulses per train) with inter-train interval (ITI) of 11 seconds (a total of 3000 stimuli per session) over the left dorsolateral prefrontal cortex (DLPFC). In the placebo condition the magnetic field will be delivered in the opposite direction (away from the brain).
Study: NCT05506657

Intervention type: OTHER
Group type: OTHER
Intervention: Center Facilitator-Coordinated Services
Description: A facilitator affiliated with Kessler Institute for Rehabilitation coordinates services that consider the participant's condition, needs and goals. Services participants may receive include:~* Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~* Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~* Help completing applications for services.~* Assistance communicating with my employer about my needs and ways to accommodate them.~* Referrals to and services from other health care or technology providers.